Brad Sickler
Director, Translational Medicine Bioinformatics Revolution Medicines
Seminars
Wednesday 4th February 2026
Revolutionizing Precision Oncology Through Cutting-Edge Epigenomic Biomarkers & AI-Enabled Data Solutions
10:00 am
- Integrate genomic and epigenomic insights to enhance understanding of tumor behavior
- Leverage ctDNA and epigenomic biomarkers for response prediction, cancer subtyping, and detection of treatment-emergent resistance
- Explore how Guardant Infinity and InfinityAI unite innovative testing with multimodal data solutions to deliver novel epigenomics biomarkers from research to clinic
